Click the link below to learn about the latest research using
Sapphire’s Rapid Diagnostic Test.
Our mission is to improve global cancer care through the development of novel Therapeutics for inhibiting metastatic cancer growth, Diagnostic for early cancer detection, response to treatment, and recurrence monitoring.
Dedicated to Changing Lives Through Research
Sapphire Biotech has identified a unique enzyme, Quiescin Sulfhydryl Oxidase 1 (QSOX1), which is elevated in cancer patients and can be detected earlier than circulating tumor cells. The company’s development of QSOX1 as a unique cancer biomarker has led it to important discoveries based on testing hundreds of human samples. Sapphire’s lead compound has been tested in animal studies has shown to significantly reduce tumors by two-thirds in under 20 days.
Global Demand and Growing Market Potential
With the oversight and expertise of internationally-recognized scientists and medical experts, Sapphire Biotech not only has great potential to help hundreds of millions of cancer patients throughout the U.S., but also become a strategic asset for its investors. The global cancer therapy market is experiencing a strong growth pattern with a CAGR over the next four years of 8.37% and 90% of cancer patients dying from metastatic cancer. Sapphire’s team has developed never-before-seen and proven compounds to combat metastatic cancer.
2018 Global Cancer Therapy Market Value
Estimated Global Cancer Therapy Market Value by 2024
Of cancer deaths are caused by metastatic cancer
Sapphire Biotech, Inc.
6191 Cornerstone Court, E., Suite 114
San Diego, CA 92121